Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

出版年份 2022 全文链接

标题

作者

关键词

出版物

Volume 40, Issue 6_suppl, Pages 17-17

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2022-02-17

DOI

10.1200/jco.2022.40.6_suppl.017

Explore over 38,000 international journals covering a vast array of academic fields.

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now